KRAS and lung adenocarcinoma: The levels of OX40 and OX40L were not consistently associated with major clinicopathogical variables, level of T-cell infiltration or with the presence of oncogenic mutations in EGFR/KRAS in lung adenocarcinomas (cohort#3).